aTYR PHARMA INC

An independent DSMB reviewed the Phase 3 EFZO-FIT™ study of efzofitimod for pulmonary sarcoidosis, involving 268 patients, and recommended continuing without modifications. The study evaluates efzofitimod's efficacy and safety, aiming to reduce steroid use and improve lung function and symptoms.

The Systemic Sclerosis Treatment Market is projected to grow significantly by 2034, driven by increasing prevalence, awareness, and FDA approvals like CABA-201's Orphan Drug and Fast Track Designations. Key players include Kyowa Hakko Kirin, AstraZeneca, and others, with therapies such as LUMICEF and SAPHNELO leading the pipeline. The market's expansion is also fueled by ongoing clinical trials and the development of new treatments targeting systemic sclerosis and related conditions.